ClinicalTrials.gg
Sign In
Not yet recruitingNCT07871760Updated Oct 13, 2026

Long-Term Quality Of Life And Symptom Assessment Among Recurrence-Free Patients Who Underwent Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

An observational study in Long Term, Quality of Life and Recurrence Free, sponsored by M.D. Anderson Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by M.D. Anderson Cancer Center · Observational

Updated Oct 13, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate long-term quality of life (QoL) and participant reported symptom burden in disease-free survivors who have undergone cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) at MD Anderson, with primary emphasis on overall (composite) QoL as measured by validated instruments.

Read the detailed description
  1. To explore patterns and variability in QoL across individual instrument subscales (e.g., EORTC QLQ-C30 functional and symptom domains; HADS anxiety and depression subscales).
  2. To examine associations between QoL outcomes and clinical/treatment-related variables, including time since surgery.
  3. To identify participant-reported survivorship needs, gaps in care, and potential targets for survivorship-focused interventions (e.g., development of a survivorship clinic), with particular emphasis on qualitative responses.
02

Conditions studied

  • Long Term
  • Quality of Life
  • Recurrence Free
  • Cytoreductive Surgery
  • Hyperthermic Intraperitoneal Chemotherapy
03

In context

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 3,044 studies on the registry; 578 are open to participants now.

Of its 608 completed or terminated interventional studies of FDA-regulated products, 407 (67%) have results posted.

Browse M.D. Anderson Cancer Center studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

UT MD Anderson Cancer Center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females; age ≥18 years at the time of enrollment
  2. Underwent curative-intent CRS/HIPEC at MD Anderson for gastrointestinal malignancies, including colorectal cancers, appendiceal cancers, and peritoneal mesothelioma between March 1, 2016, and June 30, 2025
  3. Had a complete cytoreduction with a completeness of cytoreduction score (CC) of 0 or 1
  4. Currently alive and at least 6 months disease-free post-CRS/HIPEC, based on clinical documentation and follow-up imaging
  5. English-speaking
  6. Capable of completing an electronic survey (via REDCap)
  7. Provides informed consent by proceeding to survey commencement

Exclusion criteria

Exclusion Criteria:

  • 1. Evidence of recurrent or active malignancy at time of chart review 2. Underwent CRS/HIPEC for non-malignant conditions (e.g., multicystic mesothelioma, well-differentiated papillary mesothelioma) 3. Underwent palliative-intent surgery or had an incomplete cytoreduction (CC-2 or CC-3) 4. Did not receive HIPEC (CRS only) 5. Received HIPEC on a clinical trial 6. Significant cognitive impairment limiting ability to provide informed consent or complete the survey 7. Non-English-speaking (due to lack of validated translations for study instruments) 8. No valid contact information or no access to electronic communication (e.g., participant portal or email)
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
300 participants (estimated)
Patient registry
No

Interventions

  • OtherQuestionnaire and Physical Exam

    All questionnaires will be complete remotely through REDCap

06

What researchers measure

Primary outcomes

  1. Quality of Life Questionnaire

    Time frame: Through study completion; an average of 1 year

07

Study locations

1 site
  • UT MD Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Dec 2027, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2026
First posted
Oct 13, 2026
StartEst.
Mar 22, 2027
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07871760
Lead sponsor
M.D. Anderson Cancer Center
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Mar 22, 2027 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Yun Song, MD
Contact
YSong9@mdanderson.org
346-722-0041
Yun Song, MD
principal investigator · UT MD Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

M.D. Anderson Cancer Center →

Start the discussion